The purpose of the study is to evaluate how the treatment affects the objective response rate, which is the proportion of patients whose tumors shrink or disappear. After enrollment, participants are randomly assigned to one of the three treatment groups and receive the assigned therapy in repeated cycles over several months, with regular clinic visits for safety checks and blood draws. Tumor changes are measured using the standard imaging criteria known as RECIST, and any adverse events are closely monitored. Blood samples are also taken to assess the drug’s pharmacokinetics, meaning how the body absorbs and clears the medication.

Key outcomes include the percentage of patients achieving tumor shrinkage, the time until the disease shows progressive disease (when the cancer grows again), and the length of time patients remain alive, referred to as overall survival. Safety information and laboratory test results are collected throughout the study to understand the treatment’s risk profile.

The main goal of the trial is to learn how safe the medicine is and how well patients can tolerate increasing doses. Participants will receive the drug in a series of treatment cycles that last about four weeks each, with the amount of medicine gradually increased in early groups to find the highest dose that can be given without unacceptable side effects.

During the study, patients will have regular check‑ups, blood tests, and scans to watch for any side effects and to see how the cancer responds. Any problems that arise will be recorded and managed by the medical team, and the study will continue until the predetermined number of treatment cycles is completed or if a participant chooses to stop early.

Participants in the study will receive either Vitamin D3 or a placebo capsule. The study will last for a period of 12 weeks, during which the effects of Vitamin D3 on fatigue levels will be monitored. The goal is to determine if Vitamin D3 can improve the quality of life for patients by reducing fatigue. The study is designed to provide insights into how personalized Vitamin D supplementation might benefit those with low vitamin D levels following colorectal cancer treatment.

The trial is named VICTORIA, which stands for “Personalized Vitamin D Supplementation for Reducing or Preventing Fatigue and Enhancing Quality of Life of Patients with Colorectal Tumor.” It is a randomized intervention trial, meaning that participants are randomly assigned to receive either the Vitamin D3 treatment or the placebo. The main objective is to assess the difference in fatigue levels between the two groups at the end of the study period. This research could potentially lead to new strategies for managing fatigue in colorectal cancer patients.

The purpose of this research is to test whether immunotherapy treatment, which usually works only for a small number of colorectal cancer patients, could be made effective for more patients when combined with other medications. The study will also look for biological markers that might help predict which patients will respond best to this treatment.

During the study, which may last up to 24 months, participants will receive a combination of these medications. The treatment involves taking temozolomide and capecitabine tablets daily, while ipilimumab and nivolumab are given through an intravenous infusion at scheduled times. Throughout the treatment, doctors will monitor how the cancer responds to these medications through regular medical check-ups and imaging tests.

The treatments being studied include belzutifan, which is taken as an oral film-coated tablet, and lenvatinib, which is taken as an oral capsule. Participants in the study will continue their current treatment regimen to monitor how the medications work over a longer period of time. The study will track overall survival, which refers to the length of time patients remain alive, and monitor any adverse events, which are side effects or unexpected medical problems that may occur during the treatment.

The investigation uses a specialized technique known as PET, which is a type of scan used to visualize how certain substances work inside the body. During the process, the substance [68Ga]BED003 is administered through an intravenous injection, meaning it is delivered directly into a vein. This substance is designed to target a specific protein found in certain tumor environments to help create clearer images. The scans are often combined with a computed tomography, which uses X-rays to create detailed pictures of the body’s internal structures.

Participants in the study will undergo imaging to see how well the new substance can identify cancer cells within the peritoneum, which is the thin layer of tissue that lines the inner wall of the abdomen and covers most of the organs. The study will monitor how the imaging agent behaves over time and check for any side effects. The goal is to determine if this new method can provide more accurate information about the presence and location of these cancers compared to standard medical practices.

Patients in this study will receive zanidatamab on its own, without combining it with other cancer treatments. The medicine will be given regularly over a treatment period that can last up to 60 weeks. The doctors will check how the tumors respond to the treatment by doing regular scans and tests. Some patients in the study may have breast cancer or cancers of the stomach and food pipe area, and they may have received a specific type of HER2-targeted therapy before, which is a treatment that works against the HER2 protein. For other types of solid tumors, patients should not have had this type of treatment before.

During the study, doctors will monitor patients carefully to see if the treatment is working and to watch for any side effects. This includes checking heart function, blood tests to see how the liver and kidneys are working, and measuring the size of the tumors. Patients will also be asked about symptoms they experience using questionnaires. The study will look at how many patients see their tumors shrink, how long the treatment keeps working, and how long patients live. Blood samples will be taken to measure the amount of medicine in the body and to check if the body makes any reaction against the medicine.

The treatment will be given as an subcutaneous injection (an injection under the skin). The medication or placebo will be administered over several weeks, with participants being monitored for a total of 16 weeks. The maximum daily dose of NGM120 will be 200 milligrams, with a total maximum dose of 2000 milligrams over the course of treatment.

Throughout the study, participants will be evaluated for changes in their body weight and overall health status. The study will also look at how well the body tolerates NGM120 and track any side effects that may occur. Various aspects of participants’ well-being will be monitored, including their fatigue levels, physical function, appetite, and ability to perform daily activities.

During the study, participants will be assigned to one of the two treatment groups to receive either Clensia or CitraFleet. The goal is to determine which preparation better allows the doctor to find adenomas, which are small growths on the lining of the colon that can potentially become cancer, and polyps, which are other types of growths found in the intestine. The study will also look at how well the bowel is cleaned and how much gas or bubbles are present during the procedure, as these can make it harder for the doctor to see clearly.

The process involves taking the assigned liquid before the medical procedure and then undergoing the colonoscopy. Information will be collected regarding how easy or pleasant the liquid was to drink and any side effects experienced, such as nausea, vomiting, or abdominal pain. The study evaluates how successfully the doctor can reach the end of the large intestine, known as the cecum, and how much time is needed to complete the examination.

The purpose of the study is to determine if this specific method of delivering medication is safe and practical for patients. During the study, the oxaliplatin is administered through an infusion, which is a process where medicine is delivered into the bloodstream through a tube. This delivery is done using an arterial access device, a small tool placed into an artery to allow medicine to be sent directly to the liver area.

During the study, participants will receive an intravenous injection, meaning the substance is delivered directly into a vein. After the injection, the imaging process will be performed to look for signs of cancer in the abdominal area. The effectiveness of the GEH300079 (68Ga) injection will be compared to standard imaging methods currently used in medical practice to see if this new method provides more accurate information about the presence and location of cancer cells.

The purpose of this study is to evaluate how well the combination of intravenous lidocaine and ropivacaine infiltration at the surgical sites helps patients recover after their colorectal surgery. Recovery will be measured using a questionnaire called the QOR-15, which assesses how well patients are doing twenty-four hours after their operation. The study will also examine whether these medications reach levels in the blood that could cause unwanted effects, and will look for any signs of medication-related problems in the first two hours after surgery. Pain levels will be measured at different times using a numbering system where patients rate their pain, both when resting and when moving.

During the study, patients will be monitored for various aspects of their recovery over a period that extends to three months after surgery. This includes tracking how much pain medication they need, when their digestive system starts working normally again, whether they experience any unusual sensations around the surgical area, and whether they develop any nerve-related pain. The study will also record any medical or surgical complications that occur, whether patients are able to start chemotherapy if needed within two months after surgery, how long patients stay in the hospital, and how satisfied patients are with their care when they leave the hospital. Blood samples will be taken to measure the levels of lidocaine and ropivacaine in the bloodstream.

The purpose of this research is to determine if combining BNT314 and BNT327 with chemotherapy is more effective and safe compared to standard treatment with bevacizumab and chemotherapy. BNT314 is given as a solution that goes directly into a vein through intravenous infusion. Similarly, BNT327 is first mixed with liquid and then also given through intravenous infusion.

The study is divided into three parts. The first two parts focus on finding the right dose and checking the safety of the treatment combination. The final part compares how well the new treatment combination works against the standard treatment. Throughout the study, doctors will monitor patients’ responses to the treatment and watch for any side effects that may occur.

The main purpose of this research is to determine if adding Melphalan treatment to the liver before starting the combination of Trifluridine-tipiracil and Bevacizumab helps to better control cancer growth in the liver compared to using Trifluridine-tipiracil and Bevacizumab alone. Trifluridine-tipiracil is given as tablets by mouth, while Bevacizumab is given through an infusion into a vein.

Throughout the study, patients will have regular medical check-ups and imaging tests to monitor their cancer. These tests will help determine how well the treatment is working and track any changes in the cancer, both in the liver and elsewhere in the body. The study will continue until the cancer shows signs of growth or until other factors require stopping the treatment.

The purpose of this research is to determine if two different dose levels of ONO-4578 given together with Opdivo and standard treatment (mFOLFOX6 plus bevacizumab) are safe and effective compared to the usual standard treatment alone. The medications will be given in different ways – some as tablets taken by mouth and others through an intravenous infusion into a vein.

During the study, participants will be randomly assigned to receive either the new combination treatment or the standard treatment. The study team will monitor how well the treatment works and track any side effects that may occur. Participants will have regular check-ups, including physical examinations and various medical tests to evaluate their response to treatment and ensure their safety throughout the study period.

The treatment plan includes several chemotherapy medications: irinotecan, oxaliplatin, fluorouracil, folinic acid, and capecitabine. These medications will be given either through an intravenous line directly into the bloodstream or, in some cases, as tablets taken by mouth. The treatment duration may last up to 12 months, depending on how well patients respond to the therapy.

The study will measure how quickly and effectively the tumors shrink after 8 weeks of treatment. Doctors will use regular imaging scans to monitor the size of tumors and track how patients respond to the treatment. The study will also track how long patients live after starting the treatment and monitor any side effects that may occur during therapy.

The purpose of the study is to determine how effective this combination of medications is when used as a first treatment for colorectal cancer. During the study, participants will receive the study medications for up to 12 months. Futibatinib is taken by mouth daily, while the other medications are given through intravenous infusions at regular intervals.

Throughout the study, doctors will monitor how the cancer responds to treatment using imaging scans. They will also track any side effects and assess how the treatment affects patients’ quality of life. The study will evaluate whether tumors shrink or disappear with this treatment combination, how long any improvements last, and how long patients live without their cancer getting worse.

The medication being studied, GSK4418959, works by inhibiting a protein called DNA Helicase Werner, which some cancer cells rely on to repair their DNA. In some parts of the study, GSK4418959 will be tested in combination with a type of immunotherapy called a PD-1 inhibitor, which helps the immune system recognize and attack cancer cells.

The study is divided into three parts. The first part will determine the appropriate dose of GSK4418959 when used alone. The second part will evaluate how well the medication works against colorectal and endometrial cancers. The third part will test GSK4418959 in combination with immunotherapy to determine the best dose for this combination approach.

The purpose of this study is to evaluate how effective telisotuzumab adizutecan is when used alone compared to standard care treatments in preventing cancer from returning. Participants in the study will have previously undergone surgery for their colorectal cancer and received at least 3 months of platinum-based chemotherapy. They must have detectable tumor DNA in their blood after completing their initial treatment, despite having no visible cancer on CT scans.

During the study, some participants will receive telisotuzumab adizutecan alone, while others will receive current standard treatments. The medication will be administered through intravenous infusion (delivered directly into a vein). The study will track how long participants remain free of disease and monitor changes in circulating tumor DNA levels in their blood over time.

Participants in the study will receive PD L 506 to see how their bodies react to it. For those with colorectal cancer, the treatment will be given multiple times, while healthy participants will receive it just once. The study will also measure the levels of certain substances called porphyrins in the urine, which may help in diagnosing the disease. These substances are naturally occurring in the body and can be affected by the treatment.

The study will take place over a period of time, with participants attending several visits to monitor their health and the effects of the treatment. The researchers will be looking for any side effects and changes in the levels of porphyrins in the urine to better understand the potential benefits and risks of using PD L 506 in treating colorectal cancer.

Participants in the study will receive these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will compare the effects of the combination of volrustomig, FOLFIRI, and bevacizumab to the effects of FOLFIRI and bevacizumab alone. The goal is to see if adding volrustomig improves outcomes for patients with colorectal cancer who do not have liver metastases, which are cancerous growths that have spread to the liver.

The study will take place over several months, with regular monitoring to assess how well the treatments are working and to check for any side effects. Participants will undergo various tests and assessments to track their progress and ensure their safety throughout the trial. The ultimate aim is to find more effective treatment options for people with colorectal cancer, improving their quality of life and potentially extending survival.

The purpose of the study is to evaluate how well these treatments work together in patients who cannot undergo more aggressive chemotherapy options. Participants will receive these medications through an intravenous infusion, which means the drugs are given directly into a vein. The study will last for up to 24 months, during which the patients will be monitored regularly to assess the progression of their cancer and any side effects they may experience. The goal is to see if the combination of these treatments can help patients live longer without their cancer getting worse.

Throughout the study, the health and quality of life of the participants will be closely observed. This includes regular imaging tests to check the status of the cancer and questionnaires to understand how the treatments are affecting the patients’ daily lives. The study aims to provide valuable information on the effectiveness of this treatment combination for patients with advanced colorectal cancer that has the KRAS G12C mutation.

The purpose of the study is to compare how well these treatment combinations work in controlling the cancer. Participants will receive one of the treatment combinations and will be monitored over time to see how their cancer responds. The study will involve regular visits to the clinic for treatment and assessments, which will include various tests to check the progress of the cancer and the overall health of the participants.

Throughout the study, participants will receive their treatments through an infusion, which means the medication will be given directly into a vein. The study aims to provide valuable information on which treatment combination might be more effective for patients with this specific type of colorectal cancer. The trial will continue until enough information is gathered to make a clear comparison between the two treatment options.

Participants in the study will receive either the electrochemotherapy treatment or a treatment with electrical pulses and a placebo, which in this case is a harmless solution called saline. The study will monitor the effects of these treatments on the tumor and any side effects that may occur. The goal is to see if the new treatment can help make the tumors smaller and easier to remove during surgery.

The study will also look at changes in the tumor environment, such as the presence of immune cells and other factors that might affect how the tumor grows. This research is important for understanding how to improve treatment options for people with colorectal cancer and to potentially increase the chances of successful surgery. The study is expected to continue until 2026.

The trial is testing two medications, nivolumab and ipilimumab, which are given together as a combination treatment. Nivolumab, also known by its code name BMS936558, and ipilimumab, also known as BMS734016, are both types of drugs called immunotherapies. They work by helping the body’s immune system recognize and attack cancer cells more effectively. The purpose of the study is to evaluate the safety and effectiveness of these two combination treatments over a period of 24 weeks.

Participants in the study will receive the medications through an infusion, which means the drugs are given directly into the bloodstream through a vein. The study will monitor how well the treatments work and any side effects that may occur. The goal is to understand how these treatments can help manage metastatic colorectal cancer with dMMR and MSI features, providing valuable information for future cancer care.

The purpose of the study is to evaluate how well the 68Ga-FAPI-46 PET imaging works in detecting gastrointestinal cancers. Participants in the study will undergo this imaging process, which is designed to provide clear pictures of the cancerous regions. The study will compare the results of this new imaging method with previous standard imaging techniques to see if it offers better detection of cancer locations.

Throughout the study, the safety of the 68Ga-FAPI-46 PET imaging will be monitored, including any side effects that may occur. The study will also assess how the imaging results might influence treatment decisions made by doctors. This research aims to improve the understanding of how effective this imaging method is in identifying and managing gastrointestinal cancers.

The purpose of the study is to learn more about the safety and potential benefits of AZD0022 for people with these cancers. Participants will receive the medication and be monitored to see how their bodies respond. Some participants may receive AZD0022 alone, while others may receive it alongside other cancer drugs. The study will also look at how the drug moves through the body over time. This information will help researchers understand the best way to use AZD0022 in treating these cancers.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their cancer. The study will also collect information on any side effects experienced by participants. This trial is an important step in finding new ways to treat cancers with the KRAS-G12D mutation and could lead to new treatment options for patients in the future.

The purpose of the study is to assess the clinical behavior of metastatic colorectal cancer and determine the overall possibility of surgically removing the cancer, as well as to observe any complications after surgery and the outcomes for patients. Participants in the study will receive either Fluorouracil or Capecitabine as part of their treatment plan. The study will monitor the patients over a period to gather information on how well the treatments work and the overall health and recovery of the patients.

This research is important for improving the understanding of metastatic colorectal cancer and finding better ways to treat it. By studying the effects of these medications and the potential for surgery, the study aims to provide valuable insights that could lead to improved treatment strategies and outcomes for patients with this type of cancer.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

The purpose of this study is to evaluate how effective the combination of avelumab and cetuximab is compared to using cetuximab alone in patients who have already received treatment for their cancer. Participants in the study will receive these medications through an intravenous infusion, which means the medicine is given directly into a vein. The study will last for a period of up to 12 months, during which the participants’ health and response to the treatment will be closely monitored.

Throughout the study, researchers will assess various outcomes, including the overall survival time, which is the length of time patients live after starting the treatment. They will also look at how many patients experience a reduction in cancer size and how long patients live without the cancer getting worse. Safety will be monitored by checking for any side effects and conducting regular health assessments. This study aims to provide valuable information on whether the combination of avelumab and cetuximab can offer better outcomes for patients with metastatic colorectal cancer.

Participants in the study will receive either the combination of D,L-methadone and mFOLFOX6 or mFOLFOX6 alone. The study will be conducted in two phases. The first phase will focus on understanding the safety and appropriate dosage of D,L-methadone when used with mFOLFOX6. The second phase will assess the effectiveness of the combination in controlling the cancer. Some participants may receive a placebo instead of D,L-methadone to compare the outcomes. The study will monitor the response of the cancer to the treatment over a period of 12 weeks.

The trial aims to provide insights into whether adding D,L-methadone to the standard mFOLFOX6 treatment can improve outcomes for patients with advanced colorectal cancer. The study will also look at the overall survival, quality of life, and safety of the treatment. Additionally, researchers will examine the expression of a specific protein called the μ opioid receptor in tumor tissue to see if it affects the treatment’s effectiveness. The study is expected to continue until October 2027.

The purpose of the study is to compare the overall survival of patients receiving these treatments. Participants will be randomly assigned to different treatment groups. The study will monitor patients from the start of their treatment until the end of the study period, which is expected to last until May 2027. During this time, patients will receive their assigned treatments and undergo regular check-ups to assess their health and the progress of their treatment.

Throughout the study, the safety and side effects of the treatments will be closely monitored. The study will also evaluate other factors such as the time it takes for the disease to progress, the length of hospital stays, and the quality of life of the participants. This information will help determine the most effective treatment approach for managing colorectal liver metastases.

Participants in the study will receive either mesalamine or the placebo over a period of 24 months, with an additional follow-up period of 3 months. During this time, regular colonoscopies, which are procedures that allow doctors to look inside the colon, will be conducted to monitor for any signs of tumor development. The goal is to see if mesalamine can reduce the occurrence of colorectal tumors compared to the placebo.

The study will also gather information on the number of tumors per patient, how the tumors progress, and whether the effects of the treatment vary based on factors like a patient’s history of colorectal cancer, gender, and age. Safety data will also be collected and compared between the groups receiving mesalamine and the placebo. This research is important for understanding how to better prevent colorectal cancer in individuals with Lynch syndrome.

Participants in the study will receive one of two treatment combinations. The first group will receive a medication called Amivantamab along with chemotherapy drugs known as mFOLFOX6 or FOLFIRI. The second group will receive a medication called Cetuximab along with the same chemotherapy options, mFOLFOX6 or FOLFIRI. Amivantamab is given as a solution for injection under the skin, while Cetuximab is administered as a solution for infusion into a vein. Some participants may receive a placebo, which looks like the real treatment but does not contain the active medication.

The purpose of the study is to compare the effectiveness of these treatments in terms of how long they can prevent the cancer from getting worse. Participants will be randomly assigned to one of the treatment groups and will receive their assigned treatment over a period of time. The study will monitor the progress of the cancer using standard medical assessments to determine which treatment combination is more effective. The trial is expected to continue until 2028, with recruitment starting in 2025.

Participants in the study will receive the treatment as a solution for infusion, which means it will be given through a vein. The study will observe how the treatment affects the cancer and monitor any side effects. The trial will include regular check-ups and assessments to track the progress of the treatment. The study aims to understand how well the treatment works in shrinking the tumors and how safe it is for the patients.

The study will continue for several years, with the goal of gathering enough information to determine the treatment’s effectiveness and safety. This research is important for developing new ways to treat these challenging cancers and could potentially lead to new treatment options for patients in the future.

The purpose of the study is to compare the effectiveness of using Encorafenib and Cetuximab together with Pembrolizumab against using Pembrolizumab alone. Participants in the study will be randomly assigned to one of these two treatment groups. The study will last for up to 24 months, during which participants will receive their assigned treatment and have regular check-ups to monitor their health and the cancer’s response to the treatment.

Throughout the study, participants will have regular visits with the study team to assess their health, including blood tests and scans to check the cancer’s progress. The study aims to provide valuable information on whether the combination of these medications can offer better outcomes for patients with this specific type of metastatic colorectal cancer. The results could help improve treatment options for future patients with similar conditions.

The purpose of this study is to compare the effects of continuing standard immunotherapy with a reduced dose of the same treatment. The medications being studied include Pembrolizumab, Durvalumab, Avelumab, Nivolumab, Dostarlimab, Atezolizumab, and Cemiplimab. These medications are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. Some patients will receive the standard dose of these medications, while others will receive a reduced dose every three months.

The study will last for up to three years, during which time patients will continue to receive their assigned treatment. The main goal is to see if the reduced dose is as effective as the standard dose in keeping the cancer from getting worse. Patients will have regular check-ups and assessments to monitor their health and the progress of their cancer. The study will also look at other factors, such as the quality of life and any side effects experienced by the patients. This research aims to find the best way to use immunotherapy to treat cancer effectively while minimizing side effects.

The treatment being tested includes a new drug called ABBV-400, which is an antibody-drug conjugate. This means it is a special type of medicine that combines an antibody with a drug to target cancer cells more precisely. ABBV-400 is given together with three other medications: Fluorouracil, Folinic Acid, and Bevacizumab. These medications are already used in cancer treatment and are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to find the best dose of ABBV-400 when used with the other medications and to evaluate how well this combination works in treating the cancer. Participants in the study will receive these treatments over a period of up to 36 weeks. Some participants may receive a placebo instead of ABBV-400 to help researchers compare the effects. The study will monitor participants for any side effects and changes in their cancer to determine the safety and effectiveness of the treatment.

The purpose of this study is to see how well these medications work in shrinking the tumors before surgery. Patients will receive the treatment for a period of time before their scheduled surgery to remove the cancer. The study will monitor the response of the tumors to the treatment and any side effects that may occur. The goal is to determine if the combination of atezolizumab and tiragolumab can improve the chances of successful surgery by reducing the size of the tumors.

Throughout the study, patients will have regular check-ups and tests to assess their health and the effectiveness of the treatment. These tests may include imaging scans like PET-CT or PET-MRI, which help doctors see how the cancer is responding to the treatment. The study will also look at the rate of successful surgeries and any complications that might arise after the treatment. The trial is expected to continue until 2026, with recruitment starting in 2024.

The treatment being tested is atezolizumab, which is given as an infusion, meaning it is administered directly into the bloodstream through a vein. This study will also include a comparison with a placebo, which is a substance with no active medication, to see how effective atezolizumab is on its own. The study will last for up to 12 months, during which participants will receive the treatment and have regular check-ups to monitor their health and the status of their cancer.

Participants in the study will be closely monitored for any side effects or changes in their condition. The study aims to provide valuable information on whether atezolizumab can be a beneficial treatment option for patients with this specific type of colorectal cancer who are not suitable for standard chemotherapy. The results could potentially lead to new treatment options for these patients in the future.